Logo image of ALBIO.PA

BIOSYNEX (ALBIO.PA) Stock Fundamental Analysis

EPA:ALBIO - Euronext Paris - Matif - FR0011005933 - Common Stock - Currency: EUR

1.612  -0.08 (-4.5%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ALBIO. ALBIO was compared to 55 industry peers in the Health Care Equipment & Supplies industry. ALBIO may be in some trouble as it scores bad on both profitability and health. ALBIO is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ALBIO has reported negative net income.
ALBIO had a negative operating cash flow in the past year.
ALBIO had positive earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: ALBIO reported negative operating cash flow in multiple years.
ALBIO.PA Yearly Net Income VS EBIT VS OCF VS FCFALBIO.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M 100M

1.2 Ratios

The Return On Assets of ALBIO (-18.50%) is worse than 65.45% of its industry peers.
ALBIO has a worse Return On Equity (-37.41%) than 63.64% of its industry peers.
Industry RankSector Rank
ROA -18.5%
ROE -37.41%
ROIC N/A
ROA(3y)9.77%
ROA(5y)11.31%
ROE(3y)13.92%
ROE(5y)18.54%
ROIC(3y)N/A
ROIC(5y)N/A
ALBIO.PA Yearly ROA, ROE, ROICALBIO.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 40 60

1.3 Margins

ALBIO has a Gross Margin (47.23%) which is in line with its industry peers.
ALBIO's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for ALBIO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 47.23%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.48%
GM growth 5Y0.35%
ALBIO.PA Yearly Profit, Operating, Gross MarginsALBIO.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 40 -40

More info and screens

1

2. Health

2.1 Basic Checks

ALBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ALBIO has more shares outstanding
ALBIO has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, ALBIO has a worse debt to assets ratio.
ALBIO.PA Yearly Shares OutstandingALBIO.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M
ALBIO.PA Yearly Total Debt VS Total AssetsALBIO.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of 0.51, we must say that ALBIO is in the distress zone and has some risk of bankruptcy.
ALBIO's Altman-Z score of 0.51 is on the low side compared to the rest of the industry. ALBIO is outperformed by 61.82% of its industry peers.
A Debt/Equity ratio of 0.12 indicates that ALBIO is not too dependend on debt financing.
ALBIO's Debt to Equity ratio of 0.12 is fine compared to the rest of the industry. ALBIO outperforms 80.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF N/A
Altman-Z 0.51
ROIC/WACCN/A
WACC5.95%
ALBIO.PA Yearly LT Debt VS Equity VS FCFALBIO.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M 100M 150M

2.3 Liquidity

A Current Ratio of 0.83 indicates that ALBIO may have some problems paying its short term obligations.
The Current ratio of ALBIO (0.83) is worse than 81.82% of its industry peers.
ALBIO has a Quick Ratio of 0.83. This is a bad value and indicates that ALBIO is not financially healthy enough and could expect problems in meeting its short term obligations.
ALBIO has a worse Quick ratio (0.40) than 87.27% of its industry peers.
Industry RankSector Rank
Current Ratio 0.83
Quick Ratio 0.4
ALBIO.PA Yearly Current Assets VS Current LiabilitesALBIO.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 0.57% over the past year.
ALBIO shows a small growth in Revenue. In the last year, the Revenue has grown by 7.29%.
ALBIO shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 24.41% yearly.
EPS 1Y (TTM)0.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3.16%
Revenue 1Y (TTM)7.29%
Revenue growth 3Y-15.46%
Revenue growth 5Y24.41%
Sales Q2Q%25.9%

3.2 Future

ALBIO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 49.18% yearly.
The Revenue is expected to grow by 19.43% on average over the next years. This is quite good.
EPS Next Y103.92%
EPS Next 2Y49.18%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year23.98%
Revenue Next 2Y19.43%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ALBIO.PA Yearly Revenue VS EstimatesALBIO.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M
ALBIO.PA Yearly EPS VS EstimatesALBIO.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2 -2 4 6 8

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALBIO. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 3.40, the valuation of ALBIO can be described as very cheap.
96.36% of the companies in the same industry are more expensive than ALBIO, based on the Price/Forward Earnings ratio.
ALBIO is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.10, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 3.4
ALBIO.PA Price Earnings VS Forward Price EarningsALBIO.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALBIO.PA Per share dataALBIO.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ALBIO's earnings are expected to grow with 49.18% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y49.18%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ALBIO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOSYNEX

EPA:ALBIO (3/7/2025, 7:00:00 PM)

1.612

-0.08 (-4.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)10-19 2024-10-19
Earnings (Next)N/A N/A
Inst Owners0.47%
Inst Owner ChangeN/A
Ins Owners5.03%
Ins Owner ChangeN/A
Market Cap30.23M
Analysts86.67
Price Target12.85 (697.15%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 3.4
P/S 0.29
P/FCF N/A
P/OCF N/A
P/B 0.29
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.05
EYN/A
EPS(NY)0.47
Fwd EY29.39%
FCF(TTM)-1.1
FCFYN/A
OCF(TTM)-0.58
OCFYN/A
SpS5.55
BVpS5.51
TBVpS-0.77
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -18.5%
ROE -37.41%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 47.23%
FCFM N/A
ROA(3y)9.77%
ROA(5y)11.31%
ROE(3y)13.92%
ROE(5y)18.54%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.48%
GM growth 5Y0.35%
F-Score4
Asset Turnover0.5
Health
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 97.69%
Cap/Sales 9.27%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.83
Quick Ratio 0.4
Altman-Z 0.51
F-Score4
WACC5.95%
ROIC/WACCN/A
Cap/Depr(3y)451.9%
Cap/Depr(5y)N/A
Cap/Sales(3y)20.94%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3.16%
EPS Next Y103.92%
EPS Next 2Y49.18%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)7.29%
Revenue growth 3Y-15.46%
Revenue growth 5Y24.41%
Sales Q2Q%25.9%
Revenue Next Year23.98%
Revenue Next 2Y19.43%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-36.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year135.08%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-301.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-126.32%
OCF growth 3YN/A
OCF growth 5YN/A